157 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00043 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 12.9% inhibition at 10-6 M |
| dbacp00044 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 16.5% inhibition at 10-5 M |
| dbacp00045 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 28.1% inhibition at 10-4 M |
| dbacp00046 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 58.2% inhibition at 10-3 M |
| dbacp00067 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 10.5% inhibition at 10-6 M |
| dbacp00068 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 21.9% inhibition at 10-5 M |
| dbacp00069 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 11.8% inhibition at 10-4 M |
| dbacp00070 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 17.9% inhibition at 10-3 M |
| dbacp00094 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 10.7% inhibition at 10-6 M |
| dbacp00095 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 10.0% inhibition at 10-5 M |
| dbacp00141 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 13.6% inhibition at 10-6 M |
| dbacp00142 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 20.4% inhibition at 10-5 M |
| dbacp00143 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 14.4% inhibition at 10-4 M |
| dbacp00144 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 23.4% inhibition at 10-3 M |
| dbacp00174 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 17.0% inhibition at 10-6 M |
| dbacp00175 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 13.5% inhibition at 10-5 M |
| dbacp00176 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 13.5% inhibition at 10-4 M |
| dbacp00177 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 25.3% inhibition at 10-3 M |
| dbacp00208 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 12.2% inhibition at 10-6 M |
| dbacp00209 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 15.5% inhibition at 10-5 M |
| dbacp00210 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 24.7% inhibition at 10-4 M |
| dbacp00211 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 29.0% inhibition at 10-3 M |
| dbacp00242 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 26.4% inhibition at 10-6 M |
| dbacp00243 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 13.1% inhibition at 10-5 M |
| dbacp00244 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 14.6% inhibition at 10-4 M |
| dbacp00245 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 38.4% inhibition at 10-3 M |
| dbacp00768 | A specific Eps8/EGFR Inhibitor Peptide 327 | EFLDCFQKF | A specific Eps8/EGFR Inhibitor Peptide 327 | Immune response to tumor cell recognition | Lactate dehydrogenase (LDH)-release assay | SW620 | Colon cancer | IC50 : 102.35 ± 4.66 μM |
| dbacp00776 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 6.4 µMo/L |
| dbacp00784 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 4.3 µMo/L |
| dbacp00792 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 3.5 µMo/L |
| dbacp00800 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 5 µMo/L |
| dbacp01948 | Brevinin-1RL1 | FFPLIAGLAARFLPKIFCSITKRC | Not found | Inducing apoptosis | Cell death assay | SW480 | Not specified | IC50 : 10.37 ± 0.40 μM |
| dbacp01968 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | SW742 | Colon carcinoma | LD50 : 10 – 15 μg/ml |
| dbacp01969 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | SW742 | Colon carcinoma | LD50 : 20 – 25 μg/ml |
| dbacp01970 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | SW742 | Colon carcinoma | LD50 : 30 – 40 μg/ml |
| dbacp02044 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SW-620 | Colon cancer | IC50 : 12.7 µg/ml |
| dbacp02102 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | SW-620 | Not specified | IC50 : 12.7 µg/ml |
| dbacp03190 | HAL-1 | GMWSKILGHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 44 ± 8 µM |
| dbacp03193 | HAL-1/10 | GMWKKILGKLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 60 µM |
| dbacp03196 | HAL-1/12 | GKWSKILGHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp03199 | HAL-1/15 | GMWSKLLGHLLR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp03202 | HAL-1/17 | KMWSKILGHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp03205 | HAL-1/18 | GMWSKILKHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 18 ± 2 µM |
| dbacp03208 | HAL-1/19 | GKWKKILGHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp03211 | HAL-1/20 | GKWSKILGKLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp03214 | HAL-1/21 | GKWKKILGKLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp03217 | HAL-1/22 | gmwskilghlir | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp03220 | HAL-1/29 | GMWSKILGHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp03223 | HAL-1/4 | GMWSKILGHLKR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp03226 | HAL-1/5 | GMWKKILGHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 44 ± 5 µM |
| dbacp03229 | HAL-1/6 | GMWSKILGHLIK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp03232 | HAL-1/9 | GMWSKILGKLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 50 µM |
| dbacp03235 | HAL-2 | GKWMSLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 35 ± 3 µM |
| dbacp03238 | HAL-2/1 | GKWKSLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp03241 | HAL-2/11 | GKWLSLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 40 µM |
| dbacp03244 | HAL-2/13 | GKWMTLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 60 µM |
| dbacp03247 | HAL-2/18 | GKWMSLLKHIWK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp03250 | HAL-2/19 | GKWMSLLKHWLK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp03253 | HAL-2/2 | GKWMKLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 35 ± 5 µM |
| dbacp03256 | HAL-2/20 | GKWMSLWKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp03259 | HAL-2/22 | gkwmsllkhilk | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp03262 | HAL-2/24 | GKFMSLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp03265 | HAL-2/4 | GKWMSLLKKILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 38 ± 6 µM |
| dbacp03268 | HAL-2/6 | GKWMSFLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp03271 | HAL-2/8 | GKWMSLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp03535 | L-amino oxidase (CP-LAAO) (LAO) (EC 1.4.3.2) | MNVFFMFSLLFLAALGSCADDRNPLEECFRETDYEEFLEIARXXXXTSNPKHVVRVGAGMSGLSAAYVLAGAGHQVTVLEASERPGGRXXXXXXXXEGWYANLGPMRXXXXXXXXXXXXXKFGLNLNEFSQENDNAWYFIKXXXXXXXXXXDPGLLKYPVKPSEAGKSAGQLYEESLGKXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXFDEIVDGMDKLPTSMYQAIXXXXXXXXXXXXXXXXXXKVTVTYQTPAKXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXIFLTCTKKFWEDDGIHGGKSTTDLPSRXXXXXXXXXXXXXXVIIAYGIGDDANFFQALDFKDCADIVFNDLSLIHQLPKEEIPSFCYPSMIQKXXXXXXXXXXITTFFTPYQFQHFSEAXXXXXXXIYFAGEYTAQAHGWIDSTIK | Mangrove pit viper | Cytotoxic; Anti-proliferative; Apoptosis | Not specified | SW480 | Colon cancer | EC50 : 29.43 ± 0.48 |
| dbacp03536 | L-amino oxidase (CP-LAAO) (LAO) (EC 1.4.3.2) | MNVFFMFSLLFLAALGSCADDRNPLEECFRETDYEEFLEIARXXXXTSNPKHVVRVGAGMSGLSAAYVLAGAGHQVTVLEASERPGGRXXXXXXXXEGWYANLGPMRXXXXXXXXXXXXXKFGLNLNEFSQENDNAWYFIKXXXXXXXXXXDPGLLKYPVKPSEAGKSAGQLYEESLGKXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXFDEIVDGMDKLPTSMYQAIXXXXXXXXXXXXXXXXXXKVTVTYQTPAKXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXIFLTCTKKFWEDDGIHGGKSTTDLPSRXXXXXXXXXXXXXXVIIAYGIGDDANFFQALDFKDCADIVFNDLSLIHQLPKEEIPSFCYPSMIQKXXXXXXXXXXITTFFTPYQFQHFSEAXXXXXXXIYFAGEYTAQAHGWIDSTIK | Mangrove pit viper | Cytotoxic; Anti-proliferative; Apoptosis | Not specified | SW620 | Colon cancer | EC50 : 23.19 ± 1.57 |
| dbacp03573 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : > 83.6 µMo/L |
| dbacp03581 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : > 83.6 µMo/L |
| dbacp03592 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03616 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03624 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03687 | Lasioglossin LL-III | VNWKKILGKIIKVVK | Broad-faced Furrow Bee | Cell membrane disintegration | MTT test | SW480 | Not found | IC50 : 15.0 μM |
| dbacp04181 | LL-III | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 18 ±4 µM |
| dbacp04184 | LL-III/1 | VNWKKILAKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 12 ± 3 µM |
| dbacp04187 | LL-III/10 | KNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04190 | LL-III/11 | VNWKKIILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 48 µM |
| dbacp04193 | LL-III/12 | vnwkkilgkiikvvk | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 20 µM |
| dbacp04196 | LL-III/15 | VNFKKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 42 µM |
| dbacp04199 | LL-III/16 | VN-NAl-KKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04202 | LL-III/17 | VNWRRILGRIIRVVR | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04205 | LL-III/18 | KNWKKILKKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04208 | LL-III/19 | VNWKK-Aib-LGK-Aib-IK-Aib-VK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 28 µM |
| dbacp04211 | LL-III/2 | NVWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 11 µM |
| dbacp04214 | LL-III/22 | KNWKK-Aib-LKK-Aib-IK-Aib-VK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp04217 | LL-III/23 | VNWKKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 15 µM |
| dbacp04220 | LL-III/24 | VNWOOILGOIIOVVO | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 20 µM |
| dbacp04223 | LL-III/25 | vnwkkllgkllkvvk | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 20 µM |
| dbacp04226 | LL-III/26 | VYWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 30 µM |
| dbacp04229 | LL-III/27 | VNWKKVLGKVVKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp04232 | LL-III/3 | VNWKKILKKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp04235 | LL-III/34 | NKWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 37 µM |
| dbacp04238 | LL-III/36 | VNWKKILAKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04240 | LL-III/37 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 5 ± 1 µM |
| dbacp04241 | LL-III/37 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 13 µM |
| dbacp04244 | LL-III/4 | VNWKKILGKIKKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp04247 | LL-III/6 | VNWKKILPKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04250 | LL-III/8 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04253 | LL-III/9 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 25 ± 5 µM |
| dbacp04283 | Lovastatin nonaketide synthase | MAQSMYPNEPIVVVGSGCRFPGDANTPSKLWELLQHPRDVQSRIPKERFDVDTFYHPDGKHHGRTNAPYAYVLQDDLGAFDAAFFNIQAGEAESMDPQHRLLLETVYEAVTNAGMRIQDLQGTSTAVYVGVMTHDYETVSTRDLESIPTYSATGVAVSVASNRISYFFDWHGPSMTIDTACSSSLVAVHLAVQQLRTGQSSMAIAAGANLILGPMTFVLESKLSMLSPSGRSRMWDAGADGYARGEAVCSVVLKTLSQALRDGDTIECVIRETGVNQDGRTTGITMPNHSAQEALIKATYAQAGLDITKAEDRCQFFEAHGTGTPAGDPQEAEAIATAFFGHEQVARSDGNERAPLFVGSAKTVVGHTEGTAGLAGLMKASFAVRHGVIPPNLLFDKISPRVAPFYKNLRIPTEATQWPALPPGQPRRASVNSFGFGGTNAHAIIEEYMEPEQNQLRVSNNEDCPPMTGVLSLPLVLSAKSQRSLKIMMEEMLQFLQSHPEIHLHDLTWSLLRKRSVLPFRRAIVGHSHETIRRALEDAIEDGIVSSDFTTEVRGQPSVLGIFTGQGAQWPGMLKNLIEASPYVRNIVRELDDSLQSLPEKYRPSWTLLDQFMLEGEASNVQYATFSQPLCCAVQIVLVRLLEAARIRFTAVVGHSSGEIACAFAAGLISASLAIRIAYLRGVVSAGGARGTPGAMLAAGMSFEEAQEICELDAFEGRICVAASNSPDSVTFSGDANAIDHLKGMLEDESTFARLLKVDTAYHSHHMLPCADPYMQALEECGCAVADAGSPAGSVPWYSSVDAENRQMAARDVTAKYWKDNLVSPVLFSHAVQRAVVTHKALDIGIEVGCHPALKSPCVATIKDVLSGVDLAYTGCLERGKNDLDSFSRALAYLWERFGASSFDADEFMRAVAPDRPCMSVSKLLPAYPWDRSRRYWVESRATRHHLRGPKPHLLLGKLSEYSTPLSFQWLNFVRPRDIEWLDGHALQGQTVFPAAGYIVMAMEAALMIAGTHAKQVKLLEILDMSIDKAVIFDDEDSLVELNLTADVSRNAGEAGSMTISFKIDSCLSKEGNLSLSAKGQLALTIEDVNPRTTSASDQHHLPPPEEEHPHMNRVNINAFYHELGLMGYNYSKDFRRLHnMQRADLRASGTLDFIPLMDEGNGCPLLLHPASLDVAFQTVIGAYSSPGDRRLRCLYVPTHVDRITLVPSLCLATAESGCEKVAFNTINTYDKGDYLSGDIVVFDAEQTTLFQVENITFKPFSPPDASTDHAMFARWSWGPLTPDSLLDNPEYWATAQDKEAIPIIERIVYFYIRSFLSQLTLEERQQAAFHLQKQIEWLEQVLASAKEGRHLWYDPGWENDTEAQIEHLCTANSYHPHVRLVQRVGQHLLPTVRSNGNPFDLLDHDGLLTEFYTNTLSFGPALHYARELVAQIAHRYQSMDILEIGAGTGGATKYVLATPQLGFNSYTYTDISTGFFEQAREQFAPFEDRMVFEPLDIRRSPAEQGFEPHAYDLIIASNVLHATPDLEKTMAHARSLLKPGGQMVILEITHKEHTRLGFIFGLFADWWAGVDDGRCTEPFVSFDRWDAILKRVGFSGVDSRTTDRDANLFPTSVFSTHAIDATVEYLDAPLASSGTVKDSYPPLVVVGGQTPQSQRLLNDIKAIMPPRPLQTYKRLVDLLDAEELPMKSTFVMLTELDEELFAGLTEETFEATKLLLTYASNTVWLTENAWVQHPHQASTIGMLRSIRREHPDLGVHVLDVDAVETFDATFLVEQVLRLEEHTDELASSTTWTQEPEVSWCKGRPWIPRLKRDLARNNRMNSSRRPIYEMIDSSRAPVALQTARDSSSYFLESAETWFVPESVQQMETKTIYVHFSCPHALRVGQLGFFYLVQGHVQEGNREVPVVALAERNASIVHVRPDYIYTEADNNLSEGGGSLMVTVLAAAVLAETVISTAKCLGVTDSILVLNPPSICGQMLLHAGEEIGLQVHLATTSGNRSSVSAGDAKSWLTLHARDTDWHLRRVLPRGVQALVDLSADQSCEGLTQRMMKVLMPGCAHYRAADLFTDTVSTELHSGSRHQASLPAAYWEHVVSLARQGLPSVSEGWEVMPCTQFAAHADKTRPDLSTVISWPRESDEATLPTRVRSIDAETLFAADKTYLLVGLTGDLGRSLGRWMVQHGACHIVLTSRNPQVNPKWLAHVEELGGRVTVLSMDVTSQNSVEAGLAKLKDLHLPPVGGIAFGPLVLQDVMLNnMELPMMEMVLNPKVEGVRILHEKFSDPTSSNPLDFFVMFSSIVAVMGNPGQANYSAANCYLQALAQQRVASGLAASTIDIGAVYGVGFVTRAELEEDFNAIRFMFDSVEEHELHTLFAEAVVAGRRAVHQQEQQRKFATVLDMADLELTTGIPPLDPALKDRITFFDDPRIGNLKIPEYRGAKAGEGAAGSKGSVKEQLLQATNLDQVRQIVIDGLSAKLQVTLQIPDGESVHPTIPLIDQGVDSLGAVTVGTWFSKQLYLDLPLLKVLGGASITDLANEAAARLPPSSIPLVAATDGGAESTDNTSENEVSGREDTDLSAAATITEPSSADEDDTEPGDEDVPRSHHPLSLGQEYSWRIQQGAEDPTVFNNTIGMFMKGSIDLKRLYKALRAVLRRHEIFRTGFANVDENGMAQLVFGQTKNKVQTIQVSDRAGAEEGYRQLVQTRYNPAAGDTLRLVDFFWGQDDHLLVVAYHRLVGDGSTTENIFVEAGQLYDGTSLSPHVPQFADLAARQRAMLEDGRMEEDLAYWKKMHYRPSSIPVLPLMRPLVGNSSRSDTPNFQHCGPWQQHEAVARLDPMVAFRIKERSRKHKATPMQFYLAAYQVLLARLTDSTDLTVGLADTNRATVDEMAAMGFFANLLPLRFRDFRPHITFGEHLIATRDLVREALQHARVPYGVLLDQLGLEVPVPTSNQPAPLFQAVFDYKQGQAESGTIGGAKITEVIATRERTPYDVVLEMSDDPTKDPLLTAKLQSSRYEAHHPQAFLESYMSLLSMFSMNPALKLA | Soil mold | Induce G1 arrest and increased apoptotic cell populations at the sub-G1 phase | MTT assay | SW1736 | Human anaplastic thyroid cancer | MIC : 0 – 20 µM |
| dbacp04285 | Lovastatin nonaketide synthase, polyketide synthase component | MAQSMYPNEPIVVVGSGCRFPGDANTPSKLWELLQHPRDVQSRIPKERFDVDTFYHPDGKHHGRTNAPYAYVLQDDLGAFDAAFFNIQAGEAESMDPQHRLLLETVYEAVTNAGMRIQDLQGTSTAVYVGVMTHDYETVSTRDLENIPTYSATGVAVSVASNRISYFFDWHGPSMTIDTACSSSLVAVHLAVQQLRTGQSSMAIAAGANLILGPMTFVLESKLSMLSPSGRSRMWDAGADGYARGEAVCSVVLKTLSQALRDGDTIECVIRETGVNQDGRTTGITMPNHSAQEALIKATYAQAGLDITKAEDRCQFFEAHGTGTPAGDPQEAEAIATAFFGHEQVARSDGNERAPLFVGSAKTVVGHTEGTAGLAGLMKASFAVRHGVIPPNLLFDKISPRVAPFYKNLRIPTEATQWPALPPGQPRRASVNSFGFGGTNAHAIIEEYMEPEQNQLRVSNNEDCPPMTGVLSLPLVLSAKSQRSLKIMMEEMLQFLETHPEIHLHDLTWSLLRKRSVLPFRRAIVGHSHETIRRALEDAIEDGIVSSDFTTEVRGQPSVLGIFTGQGAQWPGMLKNLIEASPYVRSIVRELDDSLQSLPEKYRPSWTLLDQFMLEGEASNVQYASFSQPLCCAVQIVLVRLLEAARIRFTAVVGHSSGEIACAFAAGLISASVAIRIAYLRGVVSAGGARGTPGAMLAAGMSFEEAQEICELDAFEGRICVAASNSPDSVTFSGDANAIDHLKSMLEDESTFARLLRVDTAYHSHHMLPCADPYMQALEECGCAVADAGSPAGSVPWYSSVNAENRQMAARDVTAEYWKDNLVSPVLFSHAVQRAVVTHKALDIGIEVGCHPALKSPCVATIKDVLSGVDLAYTGCLERGKNDLDTFSRALAYLWERFGASSFDADEFMRAVAPDRPCMSVSKLLPAYPWDHSRRYWVESRATRHHLRGPKPHLLLGKLSEYSTPLSFQWLNFVRPRDIEWLDGHALQGQTVFPAAGYIVMAMEAALMIAGTHAKQVQLLEILDMSIDKAVIFDDEDSLVELNLTADVSRNAGEAGSMTISFKIDSCLSKEGNLSLSAKGQLALMIGDVNSRTTSASDQHHLPPPEEEHPHMNRVNIKAFYHELGLMGYNYSKDFRRLHnMQRADLRASGTIDFIPLMDEGNGCPLLLHPASLDVAFQTVIGAYSSPGDRRLRCLYVPTHVDRITLVPSLCLATAESGCEKVAFNTINTYDKGDYLSGDIAVFDAEQTTLFQVENITFKPFSPPDASTDHAMFARWSWGPLTPDSLLDNPEYWATAQDKEAIPIIERIVYFYIRSFLNQLTLEERQKAAFHLQKQIEWLEQVLASAKEGRHLWYDPGWENDTEAQIEHLCTANSYHPHVRLVQRVGQHLLPTVRSNGNPFDLLDHDGLLTEFYTNTLSFGPALHYARELVAQIAHRYQSMDILEIGAGTGGATKYVLATPQLGFNSYTYTDISTGFFEQAREQFAPFEDRMVFEPLDIRRSPAEQGFETHAYDLIIASNVLHATPDLEKTMAHARSLLKPGGQMVILEITHKEHTRLGFIFGLFADWWAGVDDGRCTEPFVSFDRWDAILKRVGFSGVDSRTTDRDANLFPTSVFSTHAIDATVEYLDAPLASSGTVKDSYPPLVVVGGQTPKSQRLLNDIKAIMPPRPLQTYKRLVDLLDAEELPMKSTFVMLTELDEELFAGLTEETFEATKLLLTYSSNTVWLTENAWVQHPHQASTIGMLRSIRREHPDLGVHVLDVDAVETFDATFLVEQVLRLEEHTDELASSTTWTQEPEVSWCKGRPWIPRLKRDLARNNRMNSSRRPIYEMIDSSRAPVALQTAPDSSSYFLESAETWFVPESVRQMETKTVYVHFSCPHALRVGQLGFFYLVQGHVQEGNREVPVVALAERNASIVHVRPDYIYTEADNNLSEGGGSLIVTVLAAAVLAETVISTAKSLGVTDSILVLNPPSICGQMLLHAGEEIGLQVHLATTSGNRSSVSAGDAKSWLTLHARDTDWHLRRVLPRGVQAFVDLSADQSCECLTQRMMKVLMPGCAHYRAADLFTDTVSTELHRGLRHQASLPAAYWEHVVSLARQGLSSVSEGWEVMPCTQFAAHADKTRPDLSTVISWPRESDKATLPTRVRSIDAETLFAADKTYLLVGLTGDLGRSLGRWMVQHGACHIVLTSRNPQVNPKWLAHVEELGGRVTVLSMDVTSENSVDAGLAKIKDLHLPPVGGIAFGPLVLQDVMLKnMELPMMEMVLNPKVEGVRILHEKFSDPTSSNPLDFFVMFSSIVAVMGNPGQANYSAANCYLQALAQQRVASGLAASTIDIGAVYGVGFVTRAELEEDFNAIRFMFDSVEEHELHTLFAEAVVAGRRAVHQQEQQRKFATVLDMADLELTTGIPPLDPALKDRITFFDDPRIGNLKIPEYRGAKAGEGAAGSKGSVKEQLLQATNLDQVRQIVIDGLSAKLQVTLQIPDGESVHPTISLIDQGVDSLGAVTVGTWFSKQLYLDLPLLKVLGGASIADLADEAAARLPPSSIPLVAATDGGAESTDNTSENEVSGREDTDLSAAATITEPSSADEDDTEPGDEDVPRSHHPLSLGQEYSWRIQQGAEDPTVFNNTIGMFMKGPIDLKRLYKALRAVLRRHEIFRTGFANVDENGMAQLVFGQTKNKVQTIQVSDRAGAEEGYRQLVQTRYNPAAGDTLRLVDFFWGQDDHLLVVAYHRLVGDGSTTENIFVEAGQLYDGRSLSPRVPQFADLAARQRAMLEDGRMEEDLAYWKEMHQRPSSIPVLPLMRPLVGNSSTSNTPNFQHCGSWQQHEAVARLDPMVAFRIKERSRKHKATPMQFYLAAYQVLLARLTDSTDLTVGLADTNRATVDEMAAMGFFANLLPLRFRDFRPHITFGEHLIATRDLVREALQHARVPYGVLLDQLGLEVPVPTSNQPAPLLQAVFDYKQGQAESGTIGGAKITEVIATRERTPYDVVLEMSDDPTKDPLLTAKLQSSRYEAHHPQAFLESYMSLLSMFSMNPALKLA | Soil mold (strain NIH 2624 / FGSC A1156) | Induce G1 arrest and increased apoptotic cell populations at the sub-G1 phase | MTT assay | SW1736 | Human anaplastic thyroid cancer | MIC : 0 – 20 µM |
| dbacp04377 | MAC1 | GFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 23 ± 4 µM |
| dbacp04380 | MAC1/1 | gfgmalkllkkvl | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 19 ± 2 µM |
| dbacp04383 | MAC1/10 | GFKMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04386 | MAC1/16 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp04389 | MAC1/19 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 68 ± 2 µM |
| dbacp04392 | MAC1/2 | AFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 16 µM |
| dbacp04395 | MAC1/20 | GFGMALOLLOOVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 35 ± 4 µM |
| dbacp04398 | MAC1/21 | GFGMALRLLRRVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 17 ± 2 µM |
| dbacp04401 | MAC1/24 | GFGMALKL-(AC6C)-KKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 16 ± 1 µM |
| dbacp04404 | MAC1/25 | GFGMALK-(AC6C)-LKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 14 ± 1 µM |
| dbacp04407 | MAC1/26 | GFGMA-(AC6C)-KLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 18 ± 1 µM |
| dbacp04410 | MAC1/3 | LFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 11 ± 1 µM |
| dbacp04413 | MAC1/4 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 49 ± 9 µM |
| dbacp04416 | MAC1/6 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 29 ± 3 µM |
| dbacp04419 | MAC1/9 | GFKMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 13 ± 3 µM |
| dbacp04422 | MAC2 | GTGLPMSERRKIMLMMR | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp04428 | Macropin 1 | GFGMALKLLKKVL | The solitary bee | Cell membrane disintegration | MTT/XTT test | SW | Not found | IC50 : 23 ± 4 μM |
| dbacp04435 | Macropin 2 | GTGLPMSERRKIMLMMR | The solitary bee | Cell membrane disintegration | MTT/XTT test | SW | Not found | IC50 : >100 μM |
| dbacp04794 | N29D | PDEDAINDALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | SW-480 | Colon cancer | > 100% cell viability at 5 µM |
| dbacp04795 | N29D | PDEDAINDALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | SW-480 | Colon cancer | 60% cell viability at 50 µM |
| dbacp04800 | N29D | PDEDAINDALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | SW-480 | Colon cancer | > 100% cell viability at 5 µM |
| dbacp04801 | N29D | PDEDAINDALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | SW-480 | Colon cancer | 60% cell viability at 50 µM |
| dbacp04806 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | SW-480 | Colon cancer | 100% cell viability at 5 µM |
| dbacp04807 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | SW-480 | Colon cancer | 40% cell viability at 50 µM |
| dbacp04812 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | SW-480 | Colon cancer | 100% cell viability at 5 µM |
| dbacp04813 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | SW-480 | Colon cancer | 40% cell viability at 50 µM |
| dbacp04818 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | SW-480 | Colon cancer | MIC : 5 µM |
| dbacp04867 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | NK-lysin | Cell membrane disintegration | PI-uptake assay | SW-480 | Leukemia cancer | LD50 : 1-4 µM |
| dbacp05024 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 11.1 µMo/L |
| dbacp05092 | P6 | WYIRKIRRFFKWLKKKLKKK | Marine invertebrates | Inducing apoptosis | MTT assay | SW-620 | Colorectal cancer | Not found |
| dbacp05943 | RGD-La | RGDLLRHVVKILEKYL | Arg-Gly-Asp(RGD) tripeptide ana temporins | Cell membrane disintegration | MTT/MTS assay | SW-1116 | Colorectal cancer | 72.69 Inhibition ratio at 50 µg/ml |
| dbacp05952 | RGD-Las | RGDLLRHVVKILSKYL | Arg-Gly-Asp(RGD) tripeptide ana temporins | Cell membrane disintegration | MTT/MTS assay | SW-1116 | Colorectal cancer | 81.465 Inhibition ratio at 50 µg/ml |
| dbacp06248 | Temporin-La | LLRHVVKILEKYL | Temporins family | Cell membrane disintegration | MTT/MTS assay | SW-1116 | Colorectal cancer | 57.62 inhibition ratio at 50 µg/ml |
| dbacp06257 | Temporin-Las | LLRHVVKILSKYL | Temporins family | Cell membrane disintegration | MTT/MTS assay | SW-1116 | Colorectal cancer | 62.73 inhibition ratio at 50 µg/ml |
| dbacp06737 | Aurein 1.2_mutant (Aurm) | GLFDIIKKIIKSF | Synthetic | Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane | MTT assay | SW-480 | Colon Cancer | 51.63% cell viability |
| dbacp06739 | Aurein 1.2_R5 (R5-Aur) | RRRRRGLFDIIKKIAESF | Synthetic | Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane | MTT assay | SW-480 | Colon Cancer | 43.89% cell viability |
| dbacp06741 | Aurein 1.2_mutant_R5 (R5-Aurm) | RRRRRGLFDIIKKIIKSF | Synthetic | Necrotic activity via cell membrane lysis and apoptotic activity through disrupting mitochondrial membrane | MTT assay | SW-480 | Colon Cancer | 40.62% cell viability |
| dbacp07085 | HB43 | FAKLLAKLAKKLL | Synthetic | Motif-driven membrane insertion triggers cytotoxicity | AlamarBlue assay | SW-480 | Colon Cancer | IC50 = 12 ± 4 μM |
| dbacp07086 | HB43 | FAKLLAKLAKKLL | Synthetic | Motif-driven membrane insertion triggers cytotoxicity | AlamarBlue assay | SW-620 | Colon Cancer | IC50 = 10 ± 1 μM |
| dbacp07089 | HB43-mut2 | FAKLLAKLAKLLK | Synthetic | Motif-driven membrane insertion triggers cytotoxicity | AlamarBlue assay | SW-480 | Colon Cancer | IC50 = 34 ± 2 μM |
| dbacp07090 | HB43-mut2 | FAKLLAKLAKLLK | Synthetic | Motif-driven membrane insertion triggers cytotoxicity | AlamarBlue assay | SW-620 | Colon Cancer | IC50 = 40 ± 3 μM |
| dbacp07093 | HB43-mut3 | FAKLLAKLARRLL | Synthetic | Motif-driven membrane insertion triggers cytotoxicity | AlamarBlue assay | SW-480 | Colon Cancer | IC50 = 8 ± 1 μM |
| dbacp07094 | HB43-mut3 | FAKLLAKLARRLL | Synthetic | Motif-driven membrane insertion triggers cytotoxicity | AlamarBlue assay | SW-620 | Colon Cancer | IC50 = 9 ± 1 μM |
| dbacp07253 | ATX-101 | MDRWLVKWKKKRKIRRRRRRRRRRR | Synthetic | PCNA interference disrupts DNA repair. | CCK-8 assay | SW-1783 | Brain Tumor | IC50 = 4.8 ± 0.2 μM |
| dbacp07287 | P264-G274 | PARDVLNTTSG | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 90.98 ± 0.75 µM |
| dbacp07288 | P264-G274 | PARDVLNTTSG | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-620 | Colorectal Cancer | EC50 = 11.28 ± 0.52 µM |
| dbacp07289 | Loop1-PS2Aa | NNETYFNAVKP | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 23.76 ± 1.25 µM |
| dbacp07290 | Loop1-PS2Aa | NNETYFNAVKP | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-620 | Colorectal Cancer | EC50 = 106.2 ± 1.67 µM |
| dbacp07291 | Loop2-PS2Aa | TYFNAVKPPITA | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 92.99 ± 0.98 µM |
| dbacp07292 | Loop2-PS2Aa | TYFNAVKPPITA | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-620 | Colorectal Cancer | EC50 = 15.95 ± 0.69 µM |
| dbacp07293 | Loop1-HCoV-229E | FKPQSGGGKCF | Alphacoronavirus (HCoV-229E) | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 125.0 ± 1.32 µM |
| dbacp07294 | A4W-GGN5 | FLGWLFKVASK | Gaegurin 5 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 98.63 ± 1.17 µM |
| dbacp07295 | A4W-GGN5 | FLGWLFKVASK | Gaegurin 5 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-620 | Colorectal Cancer | EC50 = 22.07 ± 1.63 µM |
| dbacp07948 | IL13Rα2 D1 peptide | GSETWKTIITKN | Synthetic | IL13Rα2 blockade inhibits cancer metastasis | MTT assay | SW-620 | Colorectal Cancer | inhibited IL13-stimulated cell adhesion |
| dbacp08040 | Silk Fibroin peptide | Not Available | Silkworm Cocoons | SFP induces S-phase cell-cycle arrest | MTT assay | SW-1990 | Pancreatic Cancer | IC50 = 8.005 ± 1.34 mg/ml |
| dbacp08062 | TAT-327 | RKKRRQRRREFLDCFQKF | Peptide-327 | Peptide 327 blocks Eps8–EGFR | CCK-8 assay | SW-620 | Colorectal Cancer | EC50 = 64.61 ± 1.63 μM |